AmerisourceBergen selected by Karyopharm to support Xpovio

Press enter to search
Close search
Open Menu

AmerisourceBergen selected by Karyopharm to support Xpovio

By Sandra Levy - 10/04/2019

AmerisourceBergen has been selected by Karyopharm Therapeutics to support Xpovio (selinexor). AmerisourceBergen is providing a unified commercialization approach for Xpovio, which was approved by the Food and Drug Administration on July 3.

Xpovio is a nuclear export inhibitor indicated in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma who have received at least four prior therapies and whose disease is refractory to at least two proteasome inhibitors, at least two immunomodulatory agents, and an anti-CD38 monoclonal antibody.

“We are proud to work with Karyopharm to introduce a new treatment option to our customers for patients affected by this rare disease,” said Joe Cappello, senior vice president, global specialty  and branded product strategy and access at AmerisourceBergen.

Cappello continued,“At AmerisourceBergen, we act as one unified business, offering a breadth of services and custom commercialization plans to our manufacturing partners. Through this seamless experience, we can improve product performance and increase patient access to specialized therapies like Xpovio.”

AmerisourceBergen is supporting Xpovio through the following: 

  • Specialty distribution: ASD Healthcare, one of the nation’s largest specialty pharmaceutical distributors servicing 95% of U.S. hospitals, as well as specialty pharmacies, hemophilia centers, home healthcare companies and retail pharmacies, handles distribution services. Oncology Supply provides specialty distribution to independent oncology practices nationwide.
  • GPO contracting for community oncology: AmerisourceBergen provides GPO contracting, integrated dispensing solutions and expertise through ION Solutions, the largest physician service organization and group purchasing organization specializing in the support of independent, community oncology practices.
  • Third-party logistics: ICS, a pharmaceutical third-party logistics provider with 925,000 square feet of managed warehouse space across four strategic locations, aims to increase supply chain efficiency and ensure commercial success for selinexor. ICS will support distribution to specialty pharmacies and distributors. ICS was engaged two years prior to commercialization to support API storage and preparation for launch.
  • Dispensing: AmerisourceBergen’s specialty pharmacy US Bioservices has more than two decades of experience supporting small patient populations and is dispensing Xpovio. The pharmacy also provides customized clinical care, focused on supporting adherence and patient outcomes. Physicians may submit prescriptions for selinexor to US Bioservices via phone (877.757.0667), fax (888.899.0067), ePrescribe or the MyPathpoint Prescriber Portal.